The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Decreased Serum Levels of D-Serine in Patients With Schizophrenia: Evidence in Support of the N-Methyl-D-Aspartate Receptor Hypofunction Hypothesis of Schizophrenia
Abstract
BACKGROUND: The hypofunction of the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors has been implicated in the pathophysiology of schizophrenia. Several lines of evidence suggest that D-serine may function as an endogenous agonist of the glycine site of the NMDA receptor. The aim of this study was to examine whether serum levels of D- and L-serine in patients with schizophrenia are different from those of healthy controls. METHODS: Forty-two patients with schizophrenia and 42 age- and sex-matched healthy controls were enrolled in this study. Symptoms were assessed using the Brief Psychiatric Rating Scale. Serum levels of total serine and D- and L-serine were measured by high-performance liquid chromatography. RESULTS: Serum levels of D-serine in the patients with schizophrenia were significantly (z = -3.30, P =.001) lower than those of healthy controls. In contrast, serum levels of total (D and L) serine (z = -2.40, P =.02) and L-serine (z = -2.49, P =.01) in the schizophrenic patients were significantly higher than those of controls. In addition, the percentage of D-serine in the total serine in the schizophrenic patients was significantly (z = -4.78, P<.001) lower than that of controls, suggesting that the activity of serine racemase, an enzyme catalyzing the formation of D-serine from L-serine, may have been reduced in the schizophrenic patients. CONCLUSIONS: Reduced levels of D-serine may play a role in the pathophysiology of schizophrenia, and serum D- and L-serine levels might provide a measurable biological marker for schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Practical Statistics for Medical Research.
Walter, S. D., & Altman, D. G. (1992) · Biometrics · doi:10.2307/2532320 · Cited by 11,668
Practical Statistics for Medical Research
Altman, D. G. (1990) · doi:10.1201/9780429258589 · Cited by 10,668
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia
Goff, D. C., & Coyle, J. T. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.9.1367 · Cited by 915
Schell, M. J., Molliver, M. E., & Snyder, S. H. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.9.3948 · Cited by 832
Wolosker, H., Blackshaw, S., & Snyder, S. H. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.23.13409 · Cited by 811
D-Alanine Added to Antipsychotics for the Treatment of Schizophrenia
Tsai, G. E., Yang, P., Chang, Y.-C., & Chong, M.-Y. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.06.032 · Cited by 674
The Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568
Chemistry, Nutrition, and Microbiology of d-Amino Acids
Friedman, M. (1999) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf990080u · Cited by 430
Cited by
Lisman, J. E., Coyle, J. T., Green, R. W., Javitt, D. C., Benes, F. M., Heckers, S., & Grace, A. A. (2008) · Trends in Neurosciences · doi:10.1016/j.tins.2008.02.005 · Cited by 1,010
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917
“…and reduces positive symptoms in patients with chronic schizophrenia, who are receiving concurrent typical antipsychotic medications (Tsai et al., 1998; Heresco-Levy et al., 2002) and (2) that serum and CSF levels of D-serine are reduced in schizophrenic subjects (Hashimoto et al., 2003, 2005).”
BackgroundIncreased Levels of Glutamate in Brains from Patients with Mood Disorders
Hashimoto, K., Sawa, A., & Iyo, M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.017 · Cited by 609
Self-citationJavitt, D. C. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78003-5 · Cited by 560
Converging Evidence of NMDA Receptor Hypofunction in the Pathophysiology of Schizophrenia
COYLE, J. T., TSAI, G., & GOFF, D. (2003) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1300.020 · Cited by 442
Kantrowitz, J. T., & Javitt, D. C. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.04.006 · Cited by 396
Heresco-Levy, U., Javitt, D. C., Ebstein, R., Vass, A., Lichtenberg, P., Bar, G., Catinari, S., & Ermilov, M. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.12.037 · Cited by 386
Brain–gut–microbiota axis in depression: A historical overview and future directions
Chang, L., Wei, Y., & Hashimoto, K. (2022) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2022.02.004 · Cited by 377
Self-citationPhysiological functions of D-amino acid oxidases: from yeast to humans
Pollegioni, L., Piubelli, L., Sacchi, S., Pilone, M. S., & Molla, G. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-6558-4 · Cited by 359
Targeted disruption of serine racemase affects glutamatergic neurotransmission and behavior
Basu, A. C., Tsai, G. E., Ma, C.-L., Ehmsen, J. T., Mustafa, A. K., Han, L., Jiang, Z. I., Benneyworth, M. A., Froimowitz, M. P., Lange, N., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.130 · Cited by 338
The molecular genetics of schizophrenia: new findings promise new insights
Owen, M. J., Williams, N. M., & O'Donovan, M. C. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001444 · Cited by 321
d‐Amino acids in the brain:d‐serine in neurotransmission and neurodegeneration
Wolosker, H., Dumin, E., Balan, L., & Foltyn, V. N. (2008) · The FEBS Journal · doi:10.1111/j.1742-4658.2008.06515.x · Cited by 309
The origin of NMDA receptor hypofunction in schizophrenia
Nakazawa, K., & Sapkota, K. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107426 · Cited by 275
Hashimoto, K., Engberg, G., Shimizu, E., Nordin, C., Lindström, L. H., & Iyo, M. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.04.023 · Cited by 267
“We reported that serum levels of d-serine and the ratio of d-serine to total serine were lower in patients with schizophrenia, suggesting that the activity of serine racemase may be reduced in schizophrenic patients (Hashimoto et al., 2003).”
BackgroundSelf-citationG72/G30 in Schizophrenia and Bipolar Disorder: Review and Meta-analysis
Detera-Wadleigh, S. D., & McMahon, F. J. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.01.019 · Cited by 265
Papouin, T., Dunphy, J. M., Tolman, M., Dineley, K. T., & Haydon, P. G. (2017) · Neuron · doi:10.1016/j.neuron.2017.04.021 · Cited by 243
Glutamatergic Synaptic Dysregulation in Schizophrenia: Therapeutic Implications
Coyle, J. T., Basu, A., Benneyworth, M., Balu, D., & Konopaske, G. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-25758-2_10 · Cited by 180
“In contrast to GAD67, which was associated with a significant reduction of positive neurons, the number of neurons with parvalbumin mRNA in the prefrontal cortex was unchanged in patients with schizophrenia, whereas the amount of mRNA per neuron was significantly decreased (Hashimoto et al. 2003).”
BackgroundResultHayashi, Y., Ishibashi, H., Hashimoto, K., & Nakanishi, H. (2006) · Glia · doi:10.1002/glia.20322 · Cited by 90
Self-citationMoaddel, R., Luckenbaugh, D. A., Xie, Y., Villaseñor, A., Brutsche, N. E., Machado-Vieira, R., Ramamoorthy, A., Lorenzo, M. P., Garcia, A., Bernier, M., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-014-3669-0 · Cited by 86
“…higher than the levels we determined in healthy controls using this assay, 2.61±0.74 μM (Xie et al. 2014), as well as previously reported values for healthy controls and patients with MDD, 2.06±0.05 to 2.32±0.92 μM, respectively (Hashimoto et al. 2003; Mitani et al. 2006; Alexander et al. 2013).”
BackgroundMethodResultInfluentialGlycine transport inhibitors in the treatment of schizophrenia
Javitt, D. C. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_12 · Cited by 83
Egerton, A., Fusar-Poli, P., & M. Stone, J. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212799316244 · Cited by 36
Ozeki, Y., Pickard, B. S., Kano, S.-I., Malloy, M. P., Zeledon, M., Sun, D. Q., Fujii, K., Wakui, K., Shirayama, Y., Fukushima, Y., et al. (2011) · Neuroscience Research · doi:10.1016/j.neures.2010.10.003 · Cited by 34
Self-citationMetabolomic Biomarkers in Mental Disorders: Bipolar Disorder and Schizophrenia
Quintero, M., Stanisic, D., Cruz, G., Pontes, J. G. M., Costa, T. B. B. C., & Tasic, L. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-05542-4_14 · Cited by 32
Hashimoto, K. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3735-7 · Cited by 16
Self-citationEnantioselective inhibition of d‐serine transport by (S)‐ketamine
Singh, N. S., Bernier, M., Camandola, S., Khadeer, M. A., Moaddel, R., Mattson, M. P., & Wainer, I. W. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13239 · Cited by 11
Metadata
- Authors
- Hashimoto, K., Fukushima, T., Shimizu, E., Komatsu, N., Watanabe, H., Shinoda, N., Nakazato, M., Kumakiri, C., Okada, S.-I., Hasegawa, H., Imai, K., & Iyo, M.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2003-06-01
- Volume
- 60
- Issue
- 6
- Pages
- 572
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2162836113
- Cited by
- 490
- References
- 24
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.